Cytokinetics (CYTK) reported statistically positive Phase 3 ACACIA results for aficamten in non-obstructive hypertrophic cardiomyopathy, an outcome that bodes well for Edgewise Therapeutics (EWTX), as EDG-7500 is perhaps better suited mechanistically to address diastolic dysfunction in nHCM, Raymond James tells investors in a research note. The firm, which has a Strong Buy rating on Edgewise, views EDG-7500 as the most intriguing strategic asset in development in the HCM space.
